Luvsan, Ganchudur
Loading...
Товч нэр
Luvsan, Ganchudur
Бүтэн нэр
Luvsan Ganchudur
Латин нэр
Luvsan Ganchudur
Албан тушаал
Судлаач
ORCID
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparison of Clinical Features of Hepatitis B and C Virus-Related Hepatocellular Carcinoma(Mongolian National University of Medical Sciences, 2022-09-30); ; ; Objective: To compare the clinical characteristics of hepatitis B virus-related hepatocellular carcinoma (HBV group) and C virus-related hepatocellular carcinoma (HCV group). Methods: By a single century, we analyzed the clinical characteristics of 23 patients with hepatitis B virus-related hepatocellular carcinoma (HBV group) and 34 with hepatitis C virus-related hepatocellular carcinoma (HCV group). Results: The patients in the HBV group (mean age 61.1 year) were about 6 years younger than those in the HCV group (mean age 67.1 year). Liver function, as measured by indocyanine green retention at 15 min, was better in the HBV group (17.5 %) than in the HCV group (25.4 %). A higher proportion of the HBV group (55 %) than the HCV group (44 %) had clinical stage I. T-factor differed significantly between the groups: 53 % of the HBV group were T3 - 4 compared with 41 % of the HCV group. Furthermore, a higher proportion of the HBV group was graded 2 - 3 for tumor thrombus in the portal vein (20.3 %) and had poorly differentiated hepatocellular carcinoma (7 %) compared with the HCV group (7.1 % and 5 % respectively). Univariate analysis identified poor prognostic factors for hepatocellular carcinoma as HBV, age < or = 50 year, clinical stage II-III, a high AFP level, higher number of tumors, larger tumor size, tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3. On multivariate analysis, poor prognostic factors were a high AFP level, a higher number of tumors, and tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3, but not HBV, age, clinical stage, or tumor size. In the multiple logistic regression models on the hepatitis infection, the OR for ASAT was 2.01 (95 % CI 1.41 - 6.91), statistically significant (p < 0.05). Conclusion: These results suggest that HBV itself is not a stronger prognostic factor than HCV. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Primary Hepatic Angioleiomyoma: A Case Report(2023-02); ; ; Kakumoto, AkinariBACKGROUND Primary hepatic angioleiomyoma is a rare mesenchymal tumor that is characterized by blood vessels and smooth muscle. Herein, we report an extremely rare case of primary hepatic angioleiomyoma and discuss the clinicopathological features. CASE REPORT A 60-year-old Mongolian man was diagnosed with a hepatic tumor in the second and third segments of screening in 2012. It had been under control by a physician for 10 years. The patient had discomfort and vague pain in the right side of the abdomen since April 2022. Hepatitis virus markers (hepatitis B and hepatitis C) were negative. Plain computed tomography revealed an 80-mm solitary liver lesion in the left lobe with well-defined margins and heterogeneous enhancement. A left hepatectomy was performed in May 2022. The cut surface of the tumor showed a grayish-white, elastic, hard mass with a diameter of 50×80 mm. Histological findings of the tumor revealed that it was clearly demarcated from the surrounding liver tissues with relatively clear boundaries showing thick, muscle-coated blood vessels with perivascular smooth muscle bundles. Immunohistochemical staining showed that the smooth muscle cells were strongly diffuse and positive for smooth muscle actin. CONCLUSIONS Clinically, primary hepatic angioleiomyoma should be distinguished from other types of liver tumors, especially liver cancer. In combination with our long-term observation and other case reports, we recommend general follow-up if the preoperative pathological diagnosis can be confirmed and the patient has no other symptoms.